- Home
- CDXC
as 12-30-2024 4:00pm EST
ChromaDex Corp is a bioscience company dedicated to healthy aging. It is engaged in research on nicotinamide adenine dinucleotide (NAD+), levels of which decline with age. The company is the innovator behind NAD+ precursor nicotinamide riboside (NR), commercialized as the flagship ingredient Niagen. The company has three reportable segments namely Consumer Products, Ingredients segment, and Analytical Reference Standards and Services. The majority of the revenue is earned from the Consumer Products segment.
| Founded: | 1999 | Country: | United States |
| Employees: | N/A | City: | LOS ANGELES |
| Market Cap: | 415.5M | IPO Year: | N/A |
| Target Price: | $8.00 | AVG Volume (30 days): | 623.7K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 0.02 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.36 - $7.97 | Next Earning Date: | 10-31-2024 |
| Revenue: | $91,668,000 | Revenue Growth: | 9.95% |
| Revenue Growth (this year): | 18.64% | Revenue Growth (next year): | 20.72% |
Stock Insider Trading Activity of ChromaDex Corporation (CDXC)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Jaksch Frank L Jr | CDXC | Director | Dec 13 '24 | Sell | $6.19 | 37,161 | $229,955.98 | 244,179 |
Latest ChromaDex Corporation News
CDXC Breaking Stock News: Dive into CDXC Ticker-Specific Updates for Smart Investing
Zacks
5 days ago
The Zacks Analyst Blog Highlights ADMA Biologics, Tarsus Pharmaceuticals, Stoke Therapeutics, Inc. and ChromaDex
Zacks
7 days ago
4 Drug, Biotech Stocks Rising More Than 50% in 2024 With Room to Grow
Simply Wall St.
11 days ago
3 US Growth Companies With High Insider Ownership Expecting Up To 119% Earnings Growth
Simply Wall St.
11 days ago
Exploring December 2024's US Undervalued Small Caps With Insider Buying
Simply Wall St.
21 days ago
Even though ChromaDex (NASDAQ:CDXC) has lost US$73m market cap in last 7 days, shareholders are still up 389% over 1 year
Business Wire
a month ago
ChromaDex Named to the Inc. 2024 Best in Business List in the Health Products Category
Zacks
a month ago
ChromaDex Corporation (CDXC) Hits Fresh High: Is There Still Room to Run?
Simply Wall St.
a month ago
3 US Stocks Estimated To Be Trading At Discounts Ranging From 13% To 41%
Compare CDXC vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CDXC ChromaDex Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.